Diane Young
Vermögen: 678 267 $ am 31.08.2026
Vermögen: 678 267 $ am 31.08.2026
Diane C.
Young is currently Chief Medical Officer & Senior Vice President at Celldex Therapeutics, Inc. since 2019 and serves as a Trustee at The Valerie Fund.
Former positions include Assistant Director-Clinical Investigation II at Hoffmann-La Roche, Inc. from 1988 to 1990; Director-Clinical Research at Sandoz Research Institute from 1991 to 1993; Vice President-Global Development at R.W.
Johnson Pharmaceutical Research Institute from 1992 to 2002; Chief Medical Officer & Vice President at GTx, Inc. from 2015 to 2019; and Head-Oncology Clinical Development at Novartis Oncology, Inc. Education includes undergraduate studies at Harvard University and a doctorate from Harvard Medical School.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 25.06.2026 | 17’115 ( 0.02% ) | 678 267 $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| CELLDEX THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 08.07.2019 |
The Valerie Fund
The Valerie Fund Miscellaneous Commercial ServicesCommercial Services Provides children health care services for the children who are suffering with cancer | Direktor/Vorstandsmitglied | - |
| Unternehmen | Position | Ende |
|---|---|---|
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology Engages in the discovery, development and commercialization of small molecules for the treatment of cancer | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2019 |
R.W. Johnson Pharmaceutical Research Institute | Corporate Officer/Principal | 01.11.2002 |
Sandoz Research Institute | Corporate Officer/Principal | 01.01.1993 |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions | Corporate Officer/Principal | 01.01.1990 |
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 9 |
|---|---|
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology Engages in the discovery, development and commercialization of small molecules for the treatment of cancer | Health Technology |
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions | Health Technology |
R.W. Johnson Pharmaceutical Research Institute | |
Sandoz Research Institute | |
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes immunotherapy technologies for the treatment of cancer and other diseases | Health Technology |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Valerie Fund
The Valerie Fund Miscellaneous Commercial ServicesCommercial Services Provides children health care services for the children who are suffering with cancer | Commercial Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen